14 terminated. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Terminated 14 |
| Phase 2 | 4 | Terminated 4 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) MK-2225, Placebo - Systemic Sclerosis With and Without Interstitial Lung Disease | Phase 1 | Terminated | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 5 | 2023-03-10 | 2023-11-24 |
| RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis RIC alloBMT w PTCy in refractory SSc - Systemic Sclerosis | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2022-11-18 | 2025-02-04 |
| Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis AlloRx - Systemic Sclerosis | Phase 1 | Terminated | The Foundation for Orthopaedics and Regenerative Medicine | 20 | 2022-07-04 | 2026-10-20 |
| A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) TEPEZZA, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Terminated | Amgen | 3 | 2021-11-17 | 2024-06-28 |
| A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) FCX-013, veledimex - Morphea, Scleroderma, Localized | Phase 1 / Phase 2 | Terminated | Castle Creek Biosciences, LLC. | 1 | 2019-12-18 | 2024-01-23 |
| Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Dimethyl Fumarate (DMF), Placebo Oral Tablet - Systemic Sclerosis, Pulmonary; Hypertension | Phase 1 | Terminated | Robert Lafyatis | 6 | 2016-12-01 | 2022-03-17 |
| Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis UVA1 - Systemic Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Terminated | Nicolas Hunzelmann | 9 | 2008-02-01 | 2017-05-31 |
| Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 1 | Terminated | New York Medical College | 1 | 2007-08-01 | 2014-04-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis Hematopoietic stem cell transplantation - Scleroderma | Phase 1 | Terminated | Richard Burt, MD | 8 | 2005-05-01 | 2012-12-18 |
| Treatment of Early Systemic Sclerosis by Bosentan bosentan - Systemic Sclerosis (Scleroderma) | Phase 1 / Phase 2 | Terminated | Rikshospitalet University Hospital | 30 | 2005-01-01 | 2009-06-12 |
| Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Nonmyeloablative allogeneic stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 1 | Terminated | Duke University | 4 | 2003-01-01 | 2016-06-23 |
| Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Fludarabine, Cyclophosphamide, Thymoglobulin - Scleroderma, Systemic Sclerosis | Phase 1 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 15 | 2002-07-01 | 2007-12-28 |
| Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis Thalidomide, Placebo thalidomide - Scleroderma, Systemic | Phase 1 | Terminated | NYU Langone Health | 30 | 2000-08-01 | 2016-03-11 |
Scleroderma, Diffuse (10) · Autoimmune Diseases (3) · Lupus Erythematosus, Systemic (2) · Fibrosis (1) · Hypertension, Pulmonary (1) · Scleroderma, Localized (1)
Connective Tissue Diseases (14) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Immune System Diseases (3) · Cardiovascular Diseases (1) · Hypertension (1) · Lung Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Vascular Diseases (1)
fludarabine (3) · Alemtuzumab (2) · Cyclophosphamide (2) · Bosentan (1) · Busulfan (1) · Dimethyl Fumarate (1) · Drug Delivery Systems (1) · Hematopoietic Stem Cell Transplantation (1) · Leukapheresis (1) · Saline Solution (1) · Thalidomide (1) · Ultraviolet Rays (1) · teprotumumab (1) · thymoglobulin (1) · veledimex (1)
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (1) · Amgen (1) · Castle Creek Biosciences, LLC. (1) · Duke University (1) · Kyverna Therapeutics (1) · NYU Langone Health (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · New York Medical College (1) · Nicolas Hunzelmann (1) · Richard Burt, MD (1) · Rikshospitalet University Hospital (1) · Robert Lafyatis (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The Foundation for Orthopaedics and Regenerative Medicine (1)
United States (11) · Antigua and Barbuda (1) · Argentina (1) · Canada (1) · Germany (1) · Italy (1) · Norway (1) · Switzerland (1)
Chadwick Prodromos, MD (1) · Cole Sterling, MD (1) · Jan T Gran, Professor (1) · Keith Sullivan, MD (1) · Mitchell Cairo, MD (1) · Nicolas Hunzelmann (1) · Richard Burt, MD (1) · Robert A Lafyatis, MD (1) · Robert Herberman, MD (1) · Stephen J. Oliver, MD (1)
K23AR002187 (1)